Navidea Biopharmaceuticals (NYSE: NAVB) is one of 31 public companies in the “Diagnostic substances” industry, but how does it contrast to its rivals? We will compare Navidea Biopharmaceuticals to related companies based on the strength of its risk, dividends, earnings, valuation, institutional ownership, analyst recommendations and profitability.
This is a summary of recent ratings and price targets for Navidea Biopharmaceuticals and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Navidea Biopharmaceuticals Competitors||343||871||1092||103||2.40|
Volatility & Risk
Navidea Biopharmaceuticals has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals’ rivals have a beta of 1.61, suggesting that their average stock price is 61% more volatile than the S&P 500.
This table compares Navidea Biopharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Navidea Biopharmaceuticals Competitors||-971.44%||-311.54%||-44.16%|
Earnings and Valuation
This table compares Navidea Biopharmaceuticals and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Navidea Biopharmaceuticals||$660,000.00||-$10.95 million||-3.53|
|Navidea Biopharmaceuticals Competitors||$332.02 million||-$15.49 million||104.14|
Navidea Biopharmaceuticals’ rivals have higher revenue, but lower earnings than Navidea Biopharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
5.9% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 53.0% of shares of all “Diagnostic substances” companies are owned by institutional investors. 0.5% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 8.4% of shares of all “Diagnostic substances” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Navidea Biopharmaceuticals rivals beat Navidea Biopharmaceuticals on 8 of the 10 factors compared.
Navidea Biopharmaceuticals Company Profile
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. In addition, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. Further, the company is developing diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a preclinical therapeutic research collaboration with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.